MedTrace Logo

Translational Health Research Into Vascular and Neurocognitive Effects of Weight Loss

NCT07592546 · Status: NOT_YET_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 240

Last updated 2026-05-22

No results posted yet for this study

Summary

The goal of this clinical trial is to learn about the nature of brain abnormalities associated with excess body fat in healthy adults aged 35-55. The main questions it aims to answer are:

* Will excessive fat be associated with brain abnormalities on MRI measures?
* Will weight loss change brain health on MRI measures?

Participants will:

* Self-administer study drug, semaglutide, once a week for 80 weeks
* Complete metabolic and basic body measurements
* Complete cognitive, mood, and dietary assessments
* Complete questionnaires
* Undergo MRIs

Conditions

  • Class I/II Obesity

Interventions

DRUG

semaglutide

Treatment will be given for 80 weeks. Dose will be escalated from 0.25 mg to a max of 2.4 mg per week.

Sponsors & Collaborators

  • Alain Dagher

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
35 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-08-01
Primary Completion
2028-12-01
Completion
2030-06-01

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07592546 on ClinicalTrials.gov